Oncology

Articles

• 2019. D’Angelo SP et al. – Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
• 2019. Schoenborn NL et al. – Demographic, health, and attitudinal factors predictive of cancer screening decisions in older adults
• 2018. Bharmal M et al. – Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: Innovative use of patient insights
• 2018. Kaufman HL et al. – Living with Merkel cell carcinoma (MCC): Development of a conceptual model of MCC based on patient experiences
• 2018. Bharmal M et al. – How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
• 2018. Colombo N et al. – Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer
• 2018 Lambert J – Personalized oncology therapies require personalized oncology patient-reported outcome measures
• 2018. Peters ML et al. – Dutch economic value of Radium-223 in metastatic castration-resistant prostate cancer
• 2018. Kaufman HL et al. – Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma
• 2018. Cella D et al. – Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial
• 2017. Bharmal M et al. – Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
• 2017. Pavel ME et al. – Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
• 2017. Mohr PM et al. – Real world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab
• 2017. McArthur et al. – Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with Ipilimumab (INTUITION Study)
• 2017. Cooper WA et al. – Intra- and inter-observer reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer (NSCLC)
• 2017. Rosen VM et al – Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
• 2017. Zanotti G et al. – Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
• 2017. Guyot P et al – Extrapolation of survival curves from cancer trials using external information
• 2017. Cawston et al. – NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
• 2017. Leleu X et al. – Prospective longitudinal study on quality of life in relapse/refractory multiple myeloma patients receiving second- or third line lenalidomide or bortezomib treatment
• 2017. Long JA et al. – [Robot assisted radical prostatectomy: What are the evidence at the time of a specific funding?]
• 2016. Boxall N et al. – Evaluation of exposure to pioglitazone and risk of prostate cancer: A nested case–control study
• 2016. Zech J et al. – Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial
• 2016. Robinson D et al. – The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: Findings from six randomized controlled trials
• 2016. Jönsson L et al. – Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) study
• 2016. Landfeldt E et al. – Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis
• 2015. Tallman M et al. – Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States.
• 2015. Baz R et al. – Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
• 2015. Kruse et al. – Budgetary impact of treating acute promyelocytic leukemia patients with first line arsenic trioxide and retinoic acid from an Italian payer perspective
• 2015. McGuire A et al. – End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
• 2014. Cope S et al. – A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer
• 2014. Zeppetella G et al. – A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes
• 2013. Chouaid C et al. – Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: A prospective cross-sectional patient survey in a real world setting
• 2013. Cope S et al. – Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second line treatment for advanced breast cancer – A network meta-analysis with parametric survival models
• 2013. Das R et al. – Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom
• 2013. Gaultney JG et al. – Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
• 2012. Verduyn SC et al. – Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non-small cell lung cancer patients in The Netherlands
• 2012. Wimberger P et al. – Deterioration in quality of life (QoL) in patients with malignant ascites: Results from a phase II/III study comparing paracentesis plus catumaxomab to paracentesis alone
• 2012. Delforge M et al. – Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial
• 2012. Reichardt P et al. – Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study
• 2012. Dequen et al. – Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma
• 2011. Vissers DC et al. – An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer
• 2011. Gaultney JG et al. – Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
• 2010. Vissers D et al. – Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer
• 2010. Bredart A et al. – Patient satisfaction instruments for cancer clinical research or practice
• 2009. Parthan et al. – Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck

Posters & Presentations

• 2017. ESMO Immuno-Oncology Congress – Health-Related Quality of Life (HRQoL) in Patients (Pts) With Merkel Cell Carcinoma (MCC) Receiving Avelumab (81P)
• 2017. ISPOR European Congress – Minimal Impact on Patients’ Health Utilities Associated with Adverse Events in Metastatic Merkel Cell Carcinoma Patients on Treatment with Avelumab
• 2017. ISPOR European Meeting – Cost-effectiveness of nivolumab in combination with ipilimumab in first-line treatment of advanced melanoma in three European countries using 28-month overall survival from CheckMate 067
• 2017. ISPOR European Congress – Using convergent mixed methods to evaluate treatment risks and benefits in rare disease: An example from a Phase II registration trial in metastatic Merkel Cell Carcinoma
• 2017. ISPOR European Congress – Symptom deterioration in patients with metastatic renal cell carcinoma treated with cabozantinib or everolimus
• 2017. ISPOR European Congress – Estimating utilities/disutilities for high risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
• 2017. ISPOR European Congress – Impact of different baseline definitions on the incidence of relevant outcomes associated with cancer following an advanced non-small cell lung cancer (NSCLC) diagnosis
• 2017. ISPOR European Congress – Analysis of recent approvals of immuno-oncology drugs across England, Scotland, Germany and France
• 2017. ISPOR European Congress – Cost of nivolumab in combination with ipilimumab as first line treatment in advanced melanoma across various European markets
• 2017. ISPOR European Congress – Identification of real world data sources in cancer in the Nordic countries
• 2017. ISPOR European Congress – Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe
• 2017. ISOQOL Annual Conference – Long-term trends in health-related quality of life in patients with metastatic renal cell carcinoma treated with carbozantinib or everolimus
• 2017. ESMO Congress – Identifying symptom and quality of life improvements in patients with carcinoid syndrome treated with telostristat ethyl: Qualitative patient exit interviews from the TELESTAR Trial
• 2017. ASCO Annual Meeting – ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer
• 2017. ASCO Annual Meeting – Non-progression during avelumab treatment is associated with clinically relevant improvements in health-related quality of life in patients with Merkel Cell Carcinoma
• 2017. ASCO Annual Meeting – Patient experiences with avelumab vs chemotherapy for treating Merkel Cell Carcinoma: Results from protocol-specified qualitative research
• 2017. ISPOR Annual International Meeting – A systematic literature review on carcinoïd heart disease in patients with carcinoïd syndrome
• 2017. ISPOR Annual International Meeting – Psychometric validation of the FACT-M questionnaire in patients with Merkel Cell Carcinoma
• 2017. ISPOR Annual International Meeting – Non-progression on treatment with avelumab contributed to gains in health utility scores with metastatic Merkel Cell Carcinoma
• 2017. ENETS Annual Conference – Epidemiology of carcinoïd heart disease (CHD) in patients (pts) with carcinoïd syndrome (CS): A systematic literature review
• 2017. ENETS Annual Conference – What do we know about carcinoïd heart disease? A systematic literature review
• 2016. IASLC World Conference on Lung Cancer – Have we shifted the therapeutic innovation frontier? A US assessment of advanced non–small cell lung cancer (advNSCLC)
• 2016. ISPOR European Congress – Health State Utilities for Persistent, Recurrent or Metastatic Cervical Cancer in France
• 2016. ISPOR European Congress – Survival and Resource Use in the Treatment of Metastatic Renal Cell Carcinoma in Sweden – A Retrospective Analysis of Data from National Registries
• 2016. ISPOR European Congress – Baseline Characteristics and Survival of Patients Diagnosed with Advanced NSCLC in Sweden Between 2006 and 2013, Matched (1:4) to a Comparison Cohort from the General Population
• 2016. ISPOR European Congress – Patients Perspectives on Merkel Cell Carcinoma (MCC) and its Treatment with a Novel Agel (Avelumab): Findings from in-Depth Qualitative Patient Interviews
• 2016. ISPOR European Congress – Understanding the Utility Value of Patients with Heavily Pre-Treated Multiple Myeloma
• 2016. ISPOR European Congress – Development of a Guidance on the Implementation and Use of EORTC Instruments in Electronic Applications
• 2016. ISPOR European Congress – Methods for Analyzing Patient-Reported Outcomes in Oncology Trials
• 2016. ESMO – Evaluating a Novel Oncologist-led BRCA1/2 Mutation (BRCAm) Testing and Counseling Model for Patients with Ovarian cancer: Interim Results from the ENGAGE (NCT02406235) study
• 2016. EUROGIN – Estimating the Management Cost of Cervical Intraepithelial Neoplasia in the UK
• 2016. SMDM Biennal European Conference – Association of Disease Progression, Health-Related Quality of Life, and Utility in Patients with Advanced, Nonfunctional, Well-Differentiated Gastrointestinal or Lung Neuroendocrine Tumors in the Phase 3 Radiant-4 Trial
• 2016. ASCO Annual Meeting – Cost per Median Overall Month of Survival in Multiple Myeloma Patients with ≥3 Lines of Therapy or Were Double Refractory
• 2016. ASCO Annual Meeting – Association of Disease Progression, Health-Related Quality of Life, and Utility in Patients with Advanced, Nonfunctional, Well-Differentiated Gastrointestinal or Lung Neuroendocrine Tumors in the Phase 3 Radiant-4 Trial
• 2016. ISPOR Annual International Meeting – Treatment and Patient Burden in ER+/ HER2-Metastatic Breast Cancer: Results from a Physician Survey in the United States
• 2016. ISPOR Annual International Meeting – Clinical Characteristics, Treatment Patterns and Health Care Utilization in ER+/HER2- Metastatic Postmenopausal Breast Cancer Patients: Results from a Retrospective Medical Record Review in the United States
• 2016. ISPOR Annual International Meeting – Value of Innovation in Oncology Treatments for Patients in Sweden with Advanced or Metastatic Non-Small Cell Lung Cancer (advNSCLC)
• 2016. International Symposium on Hereditary Breast and Ovarian Cancer – Evaluating a Novel Oncologist-led BRCA Genetic Testing Counseling Model for Ovarian Cancer Patients: Interim Results from the ENGAGE Study
• 2015. ISPOR European Conference – Defining and Valuing Innovation in Oncology
• 2015. ISPOR European Congress – Regional Versus Centralized HTA: Implications for the Assessment of Cancer Drugs
• 2015. ISPOR European Congress – Cost-Effectiveness of Cetuximab in First-Line Treatment of Patients with Metastatic Colorectal Cancer in Belgium and the Netherlands
• 2015. ISPOR European Congress – Fixed Combination Netupitant and Palonosetron Is a Cost-Effective Intervention for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the UK
• 2015. ISPOR European Congress – Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with Irinotecan Based Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer. Stratifed Medicine at Work?
• 2015. ISPOR European Congress – Results of a Dutch Cost-Effectiveness Model of Radium-223 in Comparison to Cabazitaxel, Abiraterone, and Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Docetaxel
• 2015. ISOQOL Annual Conference – Health-Related Quality of Life in CLARINET, a phase III Trial of Lanreotide Autogel 120 mg in Patients with Non-Functioning Entero-Pancreatic neuroendocrine Tumour: Analytical Challenges and Statistical Solutions
• 2015. ISPOR Annual International Meeting – Cost-Effectiveness Analysis of Arsenic Trioxide for the Treatment of In-Patients with Acute Promyelocytic Leukemia
• 2014. ISPOR European Congress – Cost Effectiveness of Cetuximab in First-Line Treatment of RAS Wild-Type Metastatic Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium
• 2014. ISPOR European Congress – A Systematic Literature Review to Identify Trials in First-line RAS Wild-Type (WT) Metastatic Colorectal Cancer (MCRC) Patients
• 2013. San Antonio Breast Cancer Symposium – Comparative efficacy of everolimus and exemestane versus chemotherapy for advanced breast cancer in terms of progression-free survival
• 2013. ISPOR European Congress – Multivariate Network Meta-Analysis of Progression Free Survival and Overall Survival
• 2013. ISPOR Annual International Meeting – Patient-Reported Outcomes (PROs) Claims in Products Indicated for Treatment of Non-Small Cell Lung Carcinoma and Approved in Europe and in the United States
• 2012. ISPOR European Congress – Cost-Effectiveness Analysis of Immunonutrition for Upper Gastrointestinal Cancer Patients Undergoing Surgery in British Hospitals
• 2012. ISPOR European Congress – Converting EORTC QOL-C30 Scores to Utility Values: Is it Plausible?
• 2012. ISPOR European Congress – Joint Estimation of Progression Free Survival and Overall Survival
• 2012. ISPOR European Congress – Characteristics of Long-Acting Somatostatin (SSA) Use in Gastro-Entero-Pancreatic Neuroendocrine (GEP-NET) Tumors in the Netherlands
• 2012. ISPOR European Congress – Patient-Reported (PROs) in Antineoplastic Product Approvals in Europe and in the USA
• 2012. ISPOR European Congress – Cost-Effectiveness Analysis of Immunonutrition for Upper Gastrointestinal Cancer Patients Undergoing Surgery in British Hospitals
• 2012. ISPOR European Congress – Quality of Life in Patients with Malignant Ascites after Treatment with Catumaxomab: A Multicenter Phase II/III Study Comparing Paracentesis plus Catumaxomab with Paracentesis Alone
• 2012. ISCB Annual Conference – Analysis of time to patient-reported outcome meaningful change: Illustration from a clinical trial of catumaxomab in patients with malignant ascites
• 2012. ISPOR Annual International Meeting – Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results from a Phase III Clinical Trial
• 2012. DKK German Cancer Congress – Quality of life and ascites symptoms in patients with malignant ascites after treatment with catumaxomab – Results form a multicenter phase II/III study
• 2011. ISPOR European Congress – An Evaluation of Statistical Methods Used to Analyse Patient-Reported Outcomes (PRO) Data in Published Metastatic Cancer Studies
• 2011. ISPOR European Congress – Quality of Life in Small Cell Lung Cancer: Results of an Open-Label Phase III Clinical Trial
• 2011. ISPOR European Congress – Medico-Economic Analysis of the Impact of Malnutrition on the Post-Operative Course of Colorectal Cancer Patients
• 2011. ISPOR Annual International Meeting – Overview of Primary Endpoints, Progression Free-Survival (PFS) and Overall Survival (OS) for Non-Small Cell Lung Cancer (NSCLC): Their Value in Treatment Decisions and Patient Care
• 2010. ISPOR European Congress – Confirmation of Brief Pain Inventory Short Form (BPI-SF) ‘Worst Pain’ Item Cut-Point for the Assessment of Pain Progression in Castration-Resistant Prostate Cancer (CRPC)
• 2010. ISPOR European Congress – Utility Elicitation Study in the UK General Public for Late Stage Chronic Lymphocytic Leukaemia
• 2010. ISPOR European Congress – Mixed Treatment Comparison of Bevacizumab-Based Therapies Relative to Doublet-Chemotherapy Combinations to Estimate the Relative Efficacy in Progression Free Survival for Treatment of First-Line Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
• 2010. ISPOR Annual International Meeting – PRO Labelling Claims in Antineoplastic Agents
• 2010. ISPOR Annual International Meeting – Psychometric Validation of a Patient Questionnaire Evaluating Satisfaction with a Darbepoetin Alpha Pre-filled Device for Self-Injection (ARANESP®SURECLICKTMDEVICE), and a Home-Service (2CARE®SERVICE) in Chemotherapy-Induced Anaemic Cancer Patients
• 2010. ISPOR Annual International Meeting – Patient-Reported Outcomes Supporting Oncology Product Labeling Claims: Trends and Challenges
• 2009. ISOQOL Annual Conference – How People with Cancer Talk about Fatigue: Preliminary Findings from Published Qualitative Research
• 2009. ISOQOL Annual Conference – How People with Cancer Talk about Fatigue: Evidence from Exploratory Interviews
• 2009. ISOQOL Annual Conference – The Experience and Language of Fatigue in Cancer: Findings from the PROOF Consortium Interview Study
• 2009. ISOQOL Annual Conference – What Does Fatigue Mean? Definitions from Cancer Research and Care Guidelines
• 2009. ISPOR European Congress – Impact of Tumor Response on Health-Related Quality of Life (HRQL) in Newly Diagnosed Multiple Myeloma Patients Treated with Velcade/Prednisone (V-MP): Results from the Vista Trial
• 2009. ISPOR European Congress – Oncology Patient-Reported Claims: Maximising the Chance for Success
• 2009. ISPOR European Congress – Cost-Effectiveness of Short-Acting Opioids for Breakthrough Pain in Cancer Patients – A Scottish-Based Decision-Analysis Model
• 2009. ISPOR Annual International Meeting – Leveraging Patient-Reported Outcomes to Define Fatigue in Cancer
• 2008. ISPOR European Congress – Efficacy of Opioids in the Treatment of Breakthrough Cancer Pain: A Bayesian Mixed Treatment Comparison
• 2008. ISPOR European Congress – Health State Preference Study Mapping the Change over the Course of the Disease Process in Chronic Lymphocytic Leukaemia (CLL)
• 2006. ISPOR European Congress – Cost-Effectiveness of Fulvestrant as an Additional Endocrine Step in the Treatment Sequence for Hormone Responsive Advanced Breast Cancer